Kardigan develops targeted cardiovascular medicines aimed at modifying the underlying drivers of heart disease rather than only managing symptoms. Founded by former MyoKardia executives, it advances a late-stage pipeline that includes therapies for conditions such as genetic dilated cardiomyopathy. Its approach pairs disease biology with clinical responder identification to pursue more personalized heart treatments.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -18 | — |
| Q2 2025 | 0 | — | -57.5 | — |
| Q1 2026 | 0 | — | -56.1 | — |
| Q2 2026 | 0 | — | -116.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: G-III Apparel Group, Ltd. (GIII), Seneca Foods Corporation (SENEB), ScanSource, Inc. (SCSC), XPEL, Inc. (XPEL), InnovAge Holding Corp. (INNV), Shoals Technologies Group, Inc. (SHLS)